

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

October 2nd, 2024

Chordia was nominated as a finalist of
the Informa Pharma Intelligence Awards Japan 2024

Kanagawa, Japan, October 2nd, 2024 – Chordia Therapeutics Inc. (“Chordia”), announced that our company has been selected as a finalist for BIOTECH COMPANY OF THE YEAR and FINANCING DEAL OF THE YEAR in the Informa Pharma Intelligence Awards 2024.



This year's award winners will be announced at an awards ceremony to be held at the Palace Hotel Tokyo on October 22, 2024.

About the Citeline Pharma Intelligence Awards Japan 2024

The awards are the Japanese version of the Scrip Awards, which have been running for 19 years in the UK and are known worldwide. They recognize excellence and innovation by Japanese pharmaceutical and biotech companies and highlight Japan's important role in the global healthcare industry. The purpose of the awards is to reflect together on the achievements of the previous year and to honor the companies and individuals' industry-wide who are paving the way for the future of the pharmaceutical industry.

Website: <https://www.citeline.com/en/awards/citelinejapanawards>

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

ir@chorditherapeutics.com



About Chordia Therapeutics

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers.

Chordia's lead asset, CLK inhibitor CTX-712, is under Phase 1/2 clinical study in the US. CTX-712 potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to CTX-712, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Representative: Hiroshi Miyake, Representative Director
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact, IR Mizobe: ir@chorditherapeutics.com